Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
AY.66 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.66 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.72 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.72 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.72 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.133 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.133 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.133 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.5.1 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.5.1 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.5.1 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.43.7 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.43.7 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.43.7 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.33.1 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.33.1 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.33.1 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XDNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XDNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XDNChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.493NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.493NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.493NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.351.2 (Beta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.351.2 (Beta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.351.2 (Beta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.640.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.640.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.640.2NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.352NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.352NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.352NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.251NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.251NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.251NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
HC.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HC.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
HC.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XCJNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XCJNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XCJNChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
FT.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FT.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FT.2NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
EE.5NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EE.5NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
EE.5NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BQ.1.1.52NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.1.52NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BQ.1.1.52NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used